Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcellx Inc ( (ACLX) ) has shared an update.
On February 22, 2026, Arcellx entered into a definitive merger agreement under which Gilead Sciences will acquire the company via a tender offer and follow-on merger for $115 in cash per share plus a $5 contingent value right, implying equity value of about $7.8 billion. The deal, approved by both boards and backed by support agreements from holders of roughly 10.3% of Arcellx shares, offers a 68% premium to Arcellx’s 30‑day VWAP and is expected to close in the second quarter of 2026, subject to customary antitrust and tender conditions.
The transaction gives Gilead full ownership of anito-cel and Arcellx’s D-Domain CAR platform, eliminating existing profit-share, milestone and royalty obligations and consolidating economic upside from a potential foundational multiple myeloma therapy. On February 23, 2026, Gilead and Arcellx also disclosed that the U.S. Food and Drug Administration had accepted the Biologic License Application for anito-cel as a fourth-line treatment for relapsed or refractory multiple myeloma, with a Prescription Drug User Fee Act action date set for December 23, 2026, underscoring the strategic importance of the asset for both companies and their investors.
The most recent analyst rating on (ACLX) stock is a Hold with a $120.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.
Spark’s Take on ACLX Stock
According to Spark, TipRanks’ AI Analyst, ACLX is a Underperform.
The overall stock score for Arcellx Inc is primarily influenced by its weak financial performance, characterized by significant losses and declining revenues. Technical analysis also indicates a bearish trend, with the stock trading below key moving averages. Valuation concerns are heightened by a negative P/E ratio and lack of dividend yield. While the promising Phase 2 study results are a positive development, they do not offset the current financial and technical challenges.
To see Spark’s full report on ACLX stock, click here.
More about Arcellx Inc
Arcellx Inc. is a clinical-stage biotechnology company developing innovative immunotherapies, with a focus on cell therapies for cancer and other incurable diseases. Its lead program, anitocabtagene autoleucel (anito-cel), is a BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma, built on its proprietary D-Domain CAR platform aimed at safer, more effective and broadly accessible treatments.
Gilead Sciences, through its Kite subsidiary, has been collaborating with Arcellx since 2022 to co-develop and co-commercialize anito-cel. The program has produced deep and durable responses in trials and is supported by Phase 1 and pivotal Phase 2 data for fourth-line multiple myeloma, positioning Arcellx as a significant emerging player in the cell therapy segment of oncology.
Average Trading Volume: 1,076,547
Technical Sentiment Signal: Sell
Current Market Cap: $3.99B
See more insights into ACLX stock on TipRanks’ Stock Analysis page.